Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical development of immuno-oncology therapeutics

Cancer Letters(2025)10.1016/j.canlet.2025.217616Source: DataRank Database

Clinical development of immuno-oncology therapeutics is a research paper published in Cancer Letters (2025). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 23.69)OA: greenTopics (30)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Qi Chen ORCID,Qiang Shan ORCID,Tingbo Liang ORCID,Patrick M. Forde ORCID,Lei Zheng ORCID

Live enrichment

PubMed:40054657 PMC:PMC11930610 OpenAlex:https://openalex.org/W4408182555

National Institutes of Health

Grant: P50 CA062924

National Institutes of Health

Grant: R01 CA197296

National Institutes of Health

Grant: P01 CA247886

National Institutes of Health

Grant: R01 CA169702

National Institutes of Health

Grant: P30 CA006973

National Natural Science Foundation of China

Grant: 882103400

NCI NIH HHS

Grant: P30 CA054174

FWCI

23.69

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11930610/

publisherhttps://api.elsevier.com/content/article/PII:S0304383525001806?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383525001806?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2025.217616

Fields of Study

CAR-T cell therapy researchCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchHumansNeoplasmsImmunotherapyImmune Checkpoint InhibitorsCancer Vaccines

MeSH Terms

Immune Checkpoint InhibitorsHumansImmunotherapyNeoplasmsImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingCancer VaccinesOncolytic Virotherapy

Keywords

Clinical OncologyMedicineOncologyDrug developmentMedical physicsInternal medicineCancerPharmacologyDrugImmunotherapyPD-1FdaImmuno-oncologyImmune Checkpoint Inhibitor